JP2009532417A - チアゾリルジヒドロインダゾール - Google Patents

チアゾリルジヒドロインダゾール Download PDF

Info

Publication number
JP2009532417A
JP2009532417A JP2009503536A JP2009503536A JP2009532417A JP 2009532417 A JP2009532417 A JP 2009532417A JP 2009503536 A JP2009503536 A JP 2009503536A JP 2009503536 A JP2009503536 A JP 2009503536A JP 2009532417 A JP2009532417 A JP 2009532417A
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
alkenyl
alkynyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532417A5 (enExample
Inventor
マッティアス グラウエルト
ウド マイアー
マッティアス ホフマン
シュテファン ショイエラー
アンネ テー イェルゲンセン
アレクサンデル パウチ
トリクシ ブランドル
クリストフ ヘンケ
シュテッフェン ブライトフェルダー
クラウス アーブ
ミヒャエル ピーパー
インゴ プラグスト
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36763499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009532417(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2009532417A publication Critical patent/JP2009532417A/ja
Publication of JP2009532417A5 publication Critical patent/JP2009532417A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2009503536A 2006-04-06 2007-03-27 チアゾリルジヒドロインダゾール Pending JP2009532417A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06112297 2006-04-06
PCT/EP2007/052916 WO2007115933A1 (de) 2006-04-06 2007-03-27 Thiazolyl-dihydro-indazole

Publications (2)

Publication Number Publication Date
JP2009532417A true JP2009532417A (ja) 2009-09-10
JP2009532417A5 JP2009532417A5 (enExample) 2010-06-03

Family

ID=36763499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503536A Pending JP2009532417A (ja) 2006-04-06 2007-03-27 チアゾリルジヒドロインダゾール

Country Status (15)

Country Link
US (2) US20070238718A1 (enExample)
EP (1) EP2018387A1 (enExample)
JP (1) JP2009532417A (enExample)
KR (1) KR20090026129A (enExample)
CN (1) CN101466717A (enExample)
AR (1) AR060266A1 (enExample)
AU (1) AU2007236047A1 (enExample)
BR (1) BRPI0709743A2 (enExample)
CA (1) CA2647295A1 (enExample)
IL (1) IL194496A0 (enExample)
MX (1) MX2008012539A (enExample)
RU (1) RU2008143557A (enExample)
TW (1) TW200806680A (enExample)
WO (1) WO2007115933A1 (enExample)
ZA (1) ZA200807821B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505917A (ja) * 2009-09-28 2013-02-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法
WO2022092141A1 (ja) * 2020-10-28 2022-05-05 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体
JP2023163170A (ja) * 2022-04-27 2023-11-09 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007227681A1 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7691868B2 (en) * 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
PE20080371A1 (es) 2006-05-19 2008-04-09 Wyeth Corp N-benzoil-y-n-bencilpirrolidin-3-ilaminas como antagonistas de histamina-3
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
US20080293771A1 (en) * 2007-05-24 2008-11-27 Wyeth Azacyclylbenzamide derivatives as histamine-3 antagonists
CA2693138A1 (en) 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
PE20091617A1 (es) * 2008-03-13 2009-11-12 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
US20110230472A1 (en) * 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
EP2421872B1 (en) * 2009-04-22 2015-06-10 Boehringer Ingelheim International GmbH Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
ES2646489T3 (es) 2013-03-15 2017-12-14 Idorsia Pharmaceuticals Ltd Novedosos derivados de acrilamida como agentes contra la malaria
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009304A1 (en) * 1994-09-20 1996-03-28 G.D. Searle & Co. Benzopyranopyrazolyl derivatives for the treatment of inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091227B2 (en) * 2000-02-07 2006-08-15 Abbott Gmbh & Co. Kg Benzothiazole derivatives
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
AU2005293607A1 (en) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh PI3 kinases
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009304A1 (en) * 1994-09-20 1996-03-28 G.D. Searle & Co. Benzopyranopyrazolyl derivatives for the treatment of inflammation

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013505917A (ja) * 2009-09-28 2013-02-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法
JP2014070075A (ja) * 2009-09-28 2014-04-21 F Hoffmann-La Roche Ag ベンゾオキサゼピンpi3k阻害剤化合物及び使用方法
WO2022092141A1 (ja) * 2020-10-28 2022-05-05 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体
JPWO2022092141A1 (enExample) * 2020-10-28 2022-05-05
KR20230098215A (ko) * 2020-10-28 2023-07-03 시오노기 앤드 컴파니, 리미티드 항바이러스 활성을 갖는 아마이드 유도체
JP7358657B2 (ja) 2020-10-28 2023-10-10 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体
AU2021368444B2 (en) * 2020-10-28 2024-03-14 Shionogi & Co., Ltd. Amide derivative having antiviral activity
AU2021368444A9 (en) * 2020-10-28 2024-10-24 Shionogi & Co., Ltd. Amide derivative having antiviral activity
KR102734880B1 (ko) 2020-10-28 2024-11-27 시오노기 앤드 컴파니, 리미티드 항바이러스 활성을 갖는 아마이드 유도체
JP2023163170A (ja) * 2022-04-27 2023-11-09 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物
JP7454729B2 (ja) 2022-04-27 2024-03-22 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物

Also Published As

Publication number Publication date
KR20090026129A (ko) 2009-03-11
WO2007115933A1 (de) 2007-10-18
BRPI0709743A2 (pt) 2011-07-26
AR060266A1 (es) 2008-06-04
RU2008143557A (ru) 2010-06-20
IL194496A0 (en) 2009-08-03
MX2008012539A (es) 2008-10-10
AU2007236047A1 (en) 2007-10-18
US20090093474A1 (en) 2009-04-09
CN101466717A (zh) 2009-06-24
CA2647295A1 (en) 2007-10-18
TW200806680A (en) 2008-02-01
US20070238718A1 (en) 2007-10-11
EP2018387A1 (de) 2009-01-28
ZA200807821B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
JP2009532417A (ja) チアゾリルジヒドロインダゾール
JP5237262B2 (ja) チアゾリル−ジヒドロキナゾリン
US7517995B2 (en) Thiazolyl-dihydro-cyclopentapyrazole
JP2011529932A (ja) 置換ナフチリジン及び医薬としてのその使用
KR20090006181A (ko) 티아졸릴디하이드로인다졸
JP5303450B2 (ja) チアゾリル−ジヒドロキナゾリン
US8173699B2 (en) Compounds for the treatment of inflammatory diseases
DE102005035575A1 (de) Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen
DE102005023207A1 (de) Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100326

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100326

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20120423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120924